中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 1
Jan.  2020
Turn off MathJax
Article Contents

Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2020.01.025
  • Received Date: 2019-11-08
  • Published Date: 2020-01-20
  • Objective To investigate the ability of Child-Pugh score versus albumin-bilirubin(ALBI) grade in predicting the overall survival of hepatocellular carcinoma(HCC) patients with good liver function undergoing transarterial chemoembolization(TACE). Methods A retrospective analysis was performed for the clinical data of 185 patients with unresectable HCC who underwent TACE in Xijing Hospital of Digestive Diseases,Air Force Medical University,from January 2010 to December 2014,including epidemiological data(age,sex,and etiology),laboratory parameters(routine blood test results,hepatic and renal function,and coagulation function),and imaging data(tumor size and number). Overall survival time was calculated,and Child-Pugh score and ALBI grade were determined based on baseline data and laboratory results. Risk stratification was performed based on Child-Pugh score and ALBI grade,the Kaplan-Meier method was used to plot survival curves,and the log-rank test was used to compare overall survival. The Cox regression model was used to analyze risk factors.The time-dependent receiver operating characteristic(ROC) curve and C-index were used to compare the ability of Child-Pugh score and ALBI grade in predicting survival. Results According to Child-Pugh score,the patients with 5 points had a median survival time of25. 3 months(95% confidence interval [CI]: 20. 1-30. 5 months),and those with 6 points had a median survival time of 8. 6 months(95% CI: 7. 5-16. 9 months); there was a significant difference between them(P = 0. 002). According to ALBI grade,the patients with ALBI grade 1 had a median survival time of 29. 1 months(95% CI: 25. 9-32. 3 months),and those with ALBI grade 2 had a median survival time of 15. 1 months(95% CI: 12. 7-17. 6 months); there was a significant difference in survival tine between them(P < 0. 001).ECOG score,tumor size,number of tumors,alpha-fetoprotein,aspartate aminotransferase,albumin,total bilirubin,Child-Pugh score,and ALBI grade were associated with survival(all P < 0. 05). The three analytical models showed that after the adjustment for hazard ratio(HR) in the multivariate analysis,albumin(HR = 0. 93,95% CI: 0. 90-0. 97,P < 0. 001),bilirubin(HR = 1. 04,95% CI: 1. 02-1. 06,P < 0. 001),Child-Pugh score(HR = 1. 75,95% CI: 1. 18-2. 59,P = 0. 005),and ALBI grade(HR = 1. 82,95% CI: 1. 29-2. 59,P = 0. 001) independently predicted the overall survival of the patients. The time-dependent ROC curve analysis showed that the ability of Child-Pugh score in predicting survival tended to decrease over the time of observation,while the ability of ALBI grade remained relatively stable. These two systems had a similar ability in predicting survival within 12 months,while ALBI grade had a better ability than Child-Pugh score thereafter. Child-Pugh score had a slightly lower C-index than ALBI grade [0. 57(95% CI: 0. 53-0. 60) vs 0. 63(95% CI: 0. 57-0. 68) ]. Conclusion Both ALBI grade and Child-Pugh score can be used for prognostic stratification of HCC patients undergoing TACE alone,but ALBI grade has a better long-term predictive ability than Child-Pugh score.

     

  • loading
  • [1] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10126):1301-1314.
    [2] DURAND F,VALLA D. Assessment of prognosis of cirrhosis[J]. Semin Liver Dis,2008,28(1):110-122.
    [3] PUGH RN,MURRAY-LYON IM,DAWSON JL,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg,1973,60(8):646-649.
    [4] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.
    [5] KNOX JJ. Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival:The ALBI scoring model[J]. J Clin Oncol,2015,33(6):529-531.
    [6] TOYODA H,LAI PB,O’BEIRNE J,et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma:Application of the ALBI grade[J]. Br J Cancer,2016,114(7):744-750.
    [7] WANG YY,ZHONG JH,SU ZY,et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg,2016,103(6):725-734.
    [8] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and child-pugh classifications[J]. Liver Cancer,2017,6(3):204-215.
    [9] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.
    [10] PINATO DJ,SHARMA R,ALLARA E,et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J]. J Hepatol,2017,66(2):338-346.
    [11] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.
    [12] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
    [13] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.
    [14] SAPISOCHIN G,BARRY A,DOHERTY M,et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-totreat analysis[J]. J Hepatol,2017,67(1):92-99.
    [15] VASNANI R,GINSBURG M,AHMED O,et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation[J]. Hepatobiliary Surg Nutr,2016,5(3):225-233.
    [16] ZHAO Y,WANG WJ,GUAN S,et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma:A large-scale multicenter study of 222 patients[J]. Ann Oncol,2013,24(7):1786-1792.
    [17] SIEGHART W,HUCKE F,PECK-RADOSAVLJEVIC M. Transarterial chemoembolization:Modalities,indication,and patient selection[J]. J Hepatol,2015,62(5):1187-1195.
    [18] PINATO DJ,HOWELL J,RAMASWAMI R,et al. Review article:Delivering precision oncology in intermediate-stage liver cancer[J]. Aliment Pharmacol Ther,2017,45(12):1514-1523.
    [19] BOLONDI L,BURROUGHS A,DUFOUR JF,et al. Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma:Proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis,2012,32(4):348-359.
    [20] WANG Q,XIA D,BAI W,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:A multicentre observational study[J]. J Hepatol,2019,70(5):893-903.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1376) PDF downloads(281) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return